出品 | 妙投APP作者 | 张贝贝头图 | 视觉中国2025年以来,信达生物利好频传。先是1月2日开盘前信达生物公告,其与罗氏达成全球独家合作与许可协议,推进一款在研抗体偶联药物(ADC)的开发,在出海上有新进展。再是时隔半月,信达在1月17日公告披露其新引入的第三代EGFR-TKI肺癌靶向药物奥壹新®(利厄替尼片)获国家药监局批准上市,有望带来业绩新增量。且同日,信达生物董事长俞德超在第43届...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.